GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Item 9 Labs Corp (OTCPK:INLB) » Definitions » Intrinsic Value: Projected FCF

Item 9 Labs (Item 9 Labs) Intrinsic Value: Projected FCF : $-0.25 (As of Apr. 25, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Item 9 Labs Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-25), Item 9 Labs's Intrinsic Value: Projected FCF is $-0.25. The stock price of Item 9 Labs is $0.0001. Therefore, Item 9 Labs's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Item 9 Labs's Intrinsic Value: Projected FCF or its related term are showing as below:

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Item 9 Labs was 40.00. The lowest was 3.55. And the median was 6.01.

INLB's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.55
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Item 9 Labs Intrinsic Value: Projected FCF Historical Data

The historical data trend for Item 9 Labs's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Item 9 Labs Intrinsic Value: Projected FCF Chart

Item 9 Labs Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.18 -0.21 0.39 -0.16

Item 9 Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 -0.16 -0.20 -0.21 -0.25

Competitive Comparison of Item 9 Labs's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Item 9 Labs's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Item 9 Labs's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Item 9 Labs's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Item 9 Labs's Price-to-Projected-FCF falls into.



Item 9 Labs Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Item 9 Labs's Free Cash Flow(6 year avg) = $-4.51.

Item 9 Labs's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Jun23)*0.8)/Shares Outstanding (Diluted Average)
=(14.862653310476*-4.51312+52.649*0.8)/101.840
=-0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Item 9 Labs  (OTCPK:INLB) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Item 9 Labs's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0001/-0.24506812557517
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Item 9 Labs Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Item 9 Labs's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Item 9 Labs (Item 9 Labs) Business Description

Traded in Other Exchanges
N/A
Address
2111 E. Highland Avenue, Suite B375, Phoenix, AZ, USA, 85016
Item 9 Labs Corp is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The company also offers a dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. It also brings industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation.
Executives
Taylor Lawrence X. Iii director 2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Eric Kutscher director 2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Michael P Keskey director C/O ITEM 9 LABS, 2727 N. 3RD STREET, SUITE 201, PHOENIX AZ 85004
Douglas P Bowden director C/O ITEM 9 LABS 2727 N. 3RD STREET., SUITE 201, PHOENIX AZ 85004
Christopher Leland Wolven officer: Chief Operating Officer 5743 N 19TH ST, PHOENIX AZ 85016
Sara Gullickson director, officer: Chief Executive Officer 1709 BETHANY RD, PHOENIX AZ 85016
Andrew Douglas Bowden director 3621 N 39TH ST, PHOENIX AZ 85018
Robert E Mikkelsen officer: CFO, Secretary, Treasurer 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Patrick Sean Dugan 10 percent owner 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Andrew Poirier 10 percent owner 1946 E RANCHO DR, PHOENIX AZ 85016
Bryce Skalla director, officer: President 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Cohen Daniel E Md director, officer: President 10035 GRISTMILL RIDGE, EDEN PRAIRIE MN 55347
Hayjour Family Limited Partnership director, officer: President & CEO 10799 N 90TH STREET, SUITE 200, SCOTTSDALE AZ 85260
Jessica L Smith officer: CFO, Secretary, Treasurer 8399 E. INDIAN SCHOOL RD., SUITE 202, SCOTTSDALE AZ 85251
Lorrie Henderson officer: Chief Operating Officer 8399 E INDIAN SCHOOL RD, SUITE 202, SCOTTSDALE AZ 85251